Shilpa Medicare Ltd
NSE:SHILPAMED

Watchlist Manager
Shilpa Medicare Ltd Logo
Shilpa Medicare Ltd
NSE:SHILPAMED
Watchlist
Price: 912.8 INR -2.48% Market Closed
Market Cap: 89.3B INR
Have any thoughts about
Shilpa Medicare Ltd?
Write Note

Shilpa Medicare Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shilpa Medicare Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Shilpa Medicare Ltd
NSE:SHILPAMED
Gross Profit
â‚ą7.7B
CAGR 3-Years
7%
CAGR 5-Years
11%
CAGR 10-Years
11%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Gross Profit
â‚ą205B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Gross Profit
â‚ą177.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Gross Profit
â‚ą398.2B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
8%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Gross Profit
â‚ą84.8B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
10%
M
Mankind Pharma Ltd
NSE:MANKIND
Gross Profit
â‚ą69.4B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shilpa Medicare Ltd
Glance View

Market Cap
89.3B INR
Industry
Pharmaceuticals

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.

SHILPAMED Intrinsic Value
1 240.91 INR
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Shilpa Medicare Ltd's Gross Profit?
Gross Profit
7.7B INR

Based on the financial report for Jun 30, 2024, Shilpa Medicare Ltd's Gross Profit amounts to 7.7B INR.

What is Shilpa Medicare Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
11%

Over the last year, the Gross Profit growth was 19%. The average annual Gross Profit growth rates for Shilpa Medicare Ltd have been 7% over the past three years , 11% over the past five years , and 11% over the past ten years .

Back to Top